脑脊液中miR-21和miR-128诊断神经胶质瘤的价值

Identification of miR-128 and miR-21 in the cerebrospinal fluid as biomarker for the diagnosis of glioma

目的探索脑脊液中微RNA(miRNA)的表达差异,为检测神经胶质瘤寻找全新的生物标志物并确定其诊断价值。方法采用荧光定量PCR(FQ-PCR)检测20例神经胶质瘤患者和20例非胶质瘤患者的脑脊液候选标志物水平,通过MannWhitney U检验和Kruskal-Wallis检验筛选差异表达的miRNA,采用受试者工作曲线(ROC curves)和曲线下面积(AUC)评价其用于诊断神经胶质瘤的诊断效能。结果 miR-21在神经胶质瘤中表达显著高于对照组(P<0.05),而miR-128在神经胶质瘤中表达显著低于对照组(P<0.05),miR-21单独诊断的AUC为0.96。灵敏度为90%,特异度为95%。miR-128和miR-21联合诊断神经胶质瘤的灵敏度和特异度均为100%。结论脑脊液中miR-128和miR-21可能是神经胶质瘤潜在的早期诊断标志物。

Objective Investigate the expression difference of miRNA in cerebrospinal fluid （CSF） to explore new biomarkers for glioma diagnosis and evaluate the diagnostic value .Methods The candidate biomarkers in CSF were detected by using FQ-PCR for 20 cases of glioma patients and 20 cases of non-glioma patients（control group） .miRNAs with significant level changes in CSF sam-ples from patients with gliomas （n=20） compared with healthy volunteers （n=20） were screened out by using Mann-Whitney U test and Kruskal-Wallis test ,and the diagnostic values were evaluated by receiver-operating characteristic curves （ROC curves）and area under the curve（AUC） .Results MiR-128 and miR-21 were differentially expressed in CSF samples from patients with gliomas compared with control group .Expression of miR-21 in glioma is significantly higher than that in the control group（P〈0 .05） ,while the expression of miR-128 in gliomas was significantly lower than that in control group（P〈0 .05） .AUC was 0 .96 when using only miR-21 as the diagnostic biomarker ,and the sensitivity was 90% ,specificity was 95% .The diagnostic sensitivity and specificity were 100% when MiR-128 and miR-21 combined .Conclusion miR-128 and miR-21 are potential markers for gliomas diagnosis in the CSF .